Eptinezumab BLA Submitted for Episodic, Chronic Migraine Prevention
Alder BioPharmaceuticals has submitted a Biologics License Application to the FDA for eptinezumab, an investigational monoclonal antibody for migraine prevention.
Chronic Migraine
Anxiety, Depression Mediate Association Between Illness Perception and Job Fulfillment in Chronic Migraine
Results suggest that it is important to develop interventions aimed at improving the quality of life in individuals with chronic migraine and to increase knowledge about headache and psychological consequences.
Alternative Treatments for Migraine: A Research Update
Acupuncture, neurostimulation, and other alternative treatments have been associated with up to a 50% reduction in headache days.
Telemedicine Effective for the Diagnosis, Treatment of Chronic Headache
Patients in both groups were satisfied with their care.
Botox Helps Reduce Migraine Severity
Previous analysis showed that treatment reduced chronic migraine frequency.
Chronic Migraine Treatment Cuts Headache Days Early On
Participants experienced a reduction in headache days as soon as 3 days post-treatment.
Updated Treatment Guidelines for the Use of Botulinum Toxin in Spasticity, Headache
Treatment of chronic, but not episodic migraine with botulinum toxin has been added to the treatment guidelines.
Next post in AAN 2016 Coverage
